US20230227887A1 - Therapeutic Drug Monitoring - Google Patents
Therapeutic Drug Monitoring Download PDFInfo
- Publication number
- US20230227887A1 US20230227887A1 US18/051,360 US202218051360A US2023227887A1 US 20230227887 A1 US20230227887 A1 US 20230227887A1 US 202218051360 A US202218051360 A US 202218051360A US 2023227887 A1 US2023227887 A1 US 2023227887A1
- Authority
- US
- United States
- Prior art keywords
- antimicrobial
- biological sample
- microbial strain
- patient
- fluorophore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012544 monitoring process Methods 0.000 title description 8
- 229940126585 therapeutic drug Drugs 0.000 title description 4
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000012472 biological sample Substances 0.000 claims abstract description 34
- 230000000813 microbial effect Effects 0.000 claims abstract description 25
- 238000000684 flow cytometry Methods 0.000 claims abstract description 24
- 239000004599 antimicrobial Substances 0.000 claims abstract description 17
- 230000003902 lesion Effects 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- DSIFMINXCSHZPQ-UHFFFAOYSA-M FUN-1 Chemical compound [I-].S1C2=CC=CC=C2[N+](C)=C1C=C(C1=CC=CC=C11)C=C(Cl)N1C1=CC=CC=C1 DSIFMINXCSHZPQ-UHFFFAOYSA-M 0.000 claims description 3
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims description 3
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims 4
- 238000005259 measurement Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 6
- 238000011002 quantification Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 19
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 19
- 108010059993 Vancomycin Proteins 0.000 description 18
- 229960003165 vancomycin Drugs 0.000 description 18
- 108010078777 Colistin Proteins 0.000 description 16
- 229960003346 colistin Drugs 0.000 description 16
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 16
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 16
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 9
- 230000036765 blood level Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000028399 Critical Illness Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000009021 linear effect Effects 0.000 description 3
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000027700 hepatic dysfunction Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- VIOJNMVMOZPCTD-BUHFOSPRSA-N 1,3-dibutyl-5-[(e)-3-(1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidin-5-yl)prop-2-enylidene]-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C1=C(O)N(CCCC)C(=O)N(CCCC)C1=O VIOJNMVMOZPCTD-BUHFOSPRSA-N 0.000 description 1
- STMRGLKPBJVVEG-UHFFFAOYSA-N 2-(2-oxopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC(=O)C)C(=O)C2=C1 STMRGLKPBJVVEG-UHFFFAOYSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
Definitions
- the present disclosure generally relates to methods and compositions for antimicrobial quantification and functional measurement.
- antimicrobials antibiotics and antifungals
- the dosage of antimicrobials does not follow a one-size-fits-all principle, and blood levels of antibiotics in patients receiving the same drug amount can vary up to 100-1000 fold [Zander, J., et al., Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study . Crit Care, 2016. 20: p. 79.].
- This high variability is caused by differences in patient characteristics such as renal clearance, liver function, and comorbidities.
- blood levels of antimicrobials can either be insufficient to combat an infection, or so high that toxicity develops.
- TDM therapeutic drug monitoring
- TDM is especially valuable for patients in whom pharmacokinetics (PK) and/or pharmacodynamics (PD) may be altered. This is the case most often among critically ill patients suffering from renal or liver insufficiency, those with severe fluid status changes or low albumin levels, or patients receiving renal replacement therapy. Critically ill patients are often affected by severe infections and need prompt and targeted antibiotic treatment. However, due to altered PK/PD profiles the normal dosage regimes are often not sufficient, or may be excessive, e.g., if renal clearance is low, drug excretion is impaired and antibiotics blood levels may become toxic.
- PK pharmacokinetics
- PD pharmacodynamics
- TDM therapeutic drug monitoring
- flow cytometry can be used.
- Antimicrobial level of the drugs can be quantified on different body fluids such as blood, urine, cerebrospinal fluid and will quickly allow, e.g., within 2 hours, the establishment of a targeted personalized treatment. This is especially important for critically ill patients with several co-morbidities such as renal and/or hepatic dysfunction.
- a method for quantifying an antimicrobial in a biological sample comprising:
- the method can further include incubating a separate aliquot of the biological sample with a microbial strain isolated or recovered or derived from the same patient and the fluorophore, and measuring a second signal of fluorescence intensity therein using flow cytometry.
- the antimicrobial can be an antibiotic or an antifungal.
- the biological sample can be one or more of serum, plasma, urine, spinal fluid, ascitic fluid and bronchial secretion or washing.
- the fluorophore can be selected from DiBAC 4 oxonol such as DiBAC 4 (3) (Bis-(1,3-Dibutylbarbituric Acid)Trimethine Oxonol), DiOC oxacarbocyanines such as DiOC 18 (3) (3,3′-Dioctadecyloxacarbocyanine Perchlorate), DHR (dihydrorhodamine), propidium iodide, or fluorescein diacetate (FDA) such as C-FDA (5(6)-Carboxyfluorescein diacetate). Other fluorophores known in the art can also be used.
- the calibrating curve can be generated using different concentrations of the antimicrobial incubated with the reference microbial strain or with a microbial strain isolated from the same patient under testing.
- FIG. 1 Diagram showing an exemplary process of the present disclosure for determining antimicrobial concentration and efficacy in a patient receiving the treatment, so as to inform about further treatment strategy.
- FIG. 2 Flow chart showing an exemplary process of the present disclosure for determining antimicrobial concentration and efficacy in a patient receiving the treatment, so as to inform about further treatment strategy.
- FIG. 3 Exemplary diagram showing the protocol of Example 1.
- FIG. 4 A Graphic representation of the amount of cells at the acquisition gate of the flow cytometer after incubation with increasing concentrations of colistin; a dose-dependent effect was achieved.
- FIG. 4 B Flow cytometry scattergrams (SSC vs FSC) representing the morphologic changes in bacterial population with the increasing concentrations of colistin; a decrease in the population percentage is evident.
- FIG. 5 A Flow cytometry analysis of Flow cytometric TDM using the Flow-cytometry Antimicrobial Susceptibility Test (FAST) dosing kit to determine the dose-dependent effect of vancomycin upon S. aureus ATCC 29213 viability, through analysis of cell morphology visualized in scatterplots.
- FAST Flow-cytometry Antimicrobial Susceptibility Test
- FIG. 5 B Flow cytometry analysis of Flow cytometric TDM using the Flow-cytometry Antimicrobial Susceptibility Test (FAST) dosing kit to determine the dose-dependent effect of vancomycin on S. aureus ATCC 29213 viability, through analysis of the intensity of cell fluorescence.
- FAST Flow-cytometry Antimicrobial Susceptibility Test
- FIG. 6 A Control vancomycin dose curve concentration of S. aureus ATCC 29213 strain.
- the control dose curve effect obtained by flow cytometry showed a linear effect between 0.5 and 4 ug/ml and the coefficient of correlation was calculated.
- FIG. 6 B Representative example of a flow cytometric scattergram showing a decrease in the bacterial population (red circle) with the concomitant increase of patient vancomycin (vanco) serum concentration.
- TDM therapeutic drug monitoring
- compositions and kits that measures both antimicrobial levels and its efficacy in biological samples of patients using reference bacterial or fungal strains and/or, whenever available, patient-derived specific bacterial/fungal cultures.
- the improved TDM dosing assay and kit is based, in some embodiments, upon flow cytometry, and can provide results quickly and accurately, e.g., within 2 hours or less. This is significantly advantageous compared to conventional TDM methods.
- the improved TDM disclosed herein can measure the cellular effects of a panel of antimicrobials (e.g., antibiotics in case of bacteria and/or antifungals in case of fungi), available in a biological sample such as blood or other body fluids. These phenotypical changes can be measured well before the effects on bacterial growth (which is the read-out of conventional methods) become apparent. Phenotypic changes, such as morphofuntional changes, membrane potential, specific membrane lesions or DNA quantity, can be assessed by flow cytometry, and antimicrobial drug efficacy can thus be quickly detected and quantified.
- a panel of antimicrobials e.g., antibiotics in case of bacteria and/or antifungals in case of fungi
- a biological sample such as blood or other body fluids.
- fluorescent probes such as DiBAC 4 and DIOC which are membrane-potential sensitive; propidium iodide, a probe that assesses the integrity of the cell membrane; or C-FDA, DHR or FUN-1 to evaluate the metabolic cell status. These probes have been shown to provide a convenient, fast and accurate read-out of the antibiotic effect upon bacteria and fungi.
- the desirable approach can be used for standardized drug concentration measurement.
- the effect of the unknown concentration of specific antimicrobial in the serum sample (or other body fluid sample) obtained from the patient can be compared with the corresponding calibration curve, thus providing a fast and easy method to quantify the effective antimicrobial concentration present in the patient’s biological samples.
- the same procedure can be performed with a bacterial or fungal isolate obtained from the same patient, using standard clinical microbiological procedures.
- Such an approach can be used to establish the effective antimicrobial concentration available in the patient’s sample against the patient-specific bacterial or fungal strain, by assessing and quantifying the cell lesion exhibited by such strain.
- various biological samples can be collected from infected patients, such as blood from blood cultures, spinal, pericardial, pleural or peritoneal fluid, urine, bronchial secretions or bronchial washing.
- Antimicrobial treatment can be initiated later, after Antimicrobial Susceptibility Test (AST). Based on the AST result, the antimicrobial therapy can be initiated.
- AST Antimicrobial Susceptibility Test
- serum or other liquid samples can be collected to quantify the amount of effective antimicrobial available at the specific site of infection to determine whether the antimicrobial is present at sufficient level at the site of infection. If not, a different (e.g., increased) amount of antimicrobial or a different antimicrobial can be administered.
- the biological sample can be incubated following different dilutions with a type or reference microbial strain and the lesion produced on the microorganism can be quantified by flow cytometry. Following comparison with standard curves the amount of active antimicrobial agent available on the biological sample can be determined.
- the TDM can be performed with this microbial isolate, instead of a reference strain.
- Antimicrobial effect obtained in the Antimicrobial Susceptibility Test (AST) in vitro can be compared with the effect of different concentrations of the same antimicrobial in biological samples. This can represent a significant advantage in the selection of therapeutic strategies. For example, if serum level of the antimicrobial is below the assumed therapeutic effective levels (e.g., in patients where therapeutic values are impossible to achieve) but is nevertheless higher than the to minimum inhibitory concentration (MIC) value, the antimicrobial should still be able to cause severe lesion on the microorganism infecting the patient; in that case, therapy does not need to be interrupted or substituted.
- MIC minimum inhibitory concentration
- the clinician can be informed about the concentration of the antimicrobial prescribed to a patient is above or below the therapeutic intervals, allowing the clinician to make the required adjustments.
- This improved TDM method is a microbiological functional method for antimicrobial drug quantification in patient’s biological samples. It is a functional assay, which allows the measurement of the activity of the drugs and not only their chemical presence.
- the TDM disclosed herein is based upon a flow cytometric assay and not on the study of the microbe’s ability to grow, it is a very fast, reproducible and accurate method.
- This improved TDM method provides significant advantages over conventional methods, considering the urgent need of an inexpensive, simple and fast method to personalize dosage of antibiotics to treat severe infections. This is due to several reasons:
- Colistin is increasingly being prescribed as a rescue treatment for infections with multidrug-resistant bacilli.
- Colistin is an old antimicrobial but, is at present, the only alternative against superbug strains like those producing carbapenemases, and multi-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Since its pharmacokinetics is not yet well known, it would be very useful to have the possibility to measure its antibacterial activity in each individual patient receiving it. Often, nephrotoxicity and, to a lesser degree, neurotoxicity can occur during systemic colistin therapy; such adverse side effects have severely limited colistin use in the past. However, these effects are largely reversible and can be managed through close drug monitoring.
- the objective of this example was to optimize the measurement of the antimicrobial activity of colistin in the patient blood using flow cytometry.
- Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as an alternative to penicillin to inhibit penicillinase-producing strains of Staphylococcus aureus .
- vancomycin is regarded as the gold standard for antibiotic treatment of MRSA infections because of its low cost and established clinical response. Due to the complexity of vancomycin pharmacokinetics and its high toxicity, the monitoring of blood level is recommended in order to obtain therapeutic success.
- Our research group has been using flow cytometry to evaluate the in vitro susceptibility profile of bacteria with great success, including to vancomycin.
- the objective of this work was to optimize the microbiology measurement of the activity of vancomycin in the patient’s blood using flow cytometry.
- S. aureus ATCC 29213 was incubated for 1 hour with serial concentrations of vancomycin (4 ⁇ g/ml to 0.03 ⁇ g/ml) in donor drug free human serum and stained with adequate fluorochrome. The intensity of fluorescence and the changes in the scattergram of the bacterial population were recorded after flow cytometry analysis. Twenty samples of serum collected from patients receiving vancomycin were obtained from the biochemistry lab. The vancomycin drug concentrations were analyzed by Architect iVancomycin (Abbott) using the Architect i1000 SR analyzer (Abbott).
- Architect iVancomycin is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative measurement of vancomycin in human serum or plasma.
- CMIA chemiluminescent microparticle immunoassay
- serum samples were incubated with the S. aureus control strain, after 10 serial dilutions (1:2) and analyzed by flow cytometry (Accury, BD) according the protocol described in Example 1.
- a flow cytometric template of cell analysis was defined in order to include the majority of the bacterial population.
- a comparison of the concentrations obtained with the Architect iVancomycin method and with the new flow cytometric method was performed using Student’s T test.
- FIGS. 5 A and 5 B following incubation of S. aureus (susceptible to low concentrations) with increasing concentration of vancomycin, a dose effect cellular lesion is evident by: the reduction on the cell density plot (percentage of cells on P1, FIG. 5 A ) and an increase of the intensity of fluorescence ( FIG. 5 B ), both facts indicating cell damage.
- the control dose curve effect obtained by flow cytometry showed a linear effect between 1 and 0.03 ⁇ g/ml and the coefficient of correlation was calculated ( FIG. 6 A ).
- Patient’s serum sample concentration was calculated using linear regression equation obtained from the control curve. Specifically, the concentration of vancomycin in the serum patient sample was determined by using the % of viable cells obtained in FIG. 6 B (red square) that was within the linearity range, and taking into consideration the serum dilution factor. An excellent correlation between both methods was obtained, with a variation of vancomycin concentration in serum patients of ⁇ 5 ⁇ g/ml.
Abstract
Disclosed herein are methods and compositions for antimicrobial quantification and functional measurement. In one aspect, a method for quantifying antimicrobial comprises: obtaining a biological sample from a patient receiving an antimicrobial; incubating the biological sample with a reference microbial strain and a fluorophore for detecting cell lesion; measuring a first signal of fluorescent intensity in the incubated biological sample using flow cytometry; and comparing the first signal to a calibrating curve previously generated for the antimicrobial, thereby quantifying the antimicrobial present in the biological sample.
Description
- This application is a continuation application of U.S. Application No. 16/617,817, filed Nov. 27, 2019, now U.S. Pat. No. 11,485,993, which is a U.S. national phase application of PCT International Patent Application No. PCT/PT2018/050021, filed on Jun. 1, 2018, which claims the benefit of and priority to U.S. Provisional Application No. 62/514,323 filed Jun. 2, 2017, the entire disclosure of each of which is incorporated herein by reference.
- The present disclosure generally relates to methods and compositions for antimicrobial quantification and functional measurement.
- Prescription of the appropriate type and dosage of antimicrobials (antibiotics and antifungals) to treat severe infections is crucial. Unfortunately, the dosage of antimicrobials does not follow a one-size-fits-all principle, and blood levels of antibiotics in patients receiving the same drug amount can vary up to 100-1000 fold [Zander, J., et al., Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study. Crit Care, 2016. 20: p. 79.]. This high variability is caused by differences in patient characteristics such as renal clearance, liver function, and comorbidities. As a result, blood levels of antimicrobials can either be insufficient to combat an infection, or so high that toxicity develops. To maximize treatment efficacy and minimize adverse side effects, dosage must be adjusted, based upon the measurement of actual blood level of antimicrobials, a process called therapeutic drug monitoring (TDM). Ideally it should follow the in vitro determination of the antimicrobial efficacy to treat the specific infection, that is the antimicrobial susceptibility testing (AST).
- TDM is especially valuable for patients in whom pharmacokinetics (PK) and/or pharmacodynamics (PD) may be altered. This is the case most often among critically ill patients suffering from renal or liver insufficiency, those with severe fluid status changes or low albumin levels, or patients receiving renal replacement therapy. Critically ill patients are often affected by severe infections and need prompt and targeted antibiotic treatment. However, due to altered PK/PD profiles the normal dosage regimes are often not sufficient, or may be excessive, e.g., if renal clearance is low, drug excretion is impaired and antibiotics blood levels may become toxic.
- Current available TDM methods for antibiotics are based on high-pressure liquid chromatography (HPLC) or immunoassays, both sharing many limitations. Firstly, they are only available for a narrow selection of antibiotics (predominantly aminoglycosides, such as amikacin and gentamicin, and vancomycin). Secondly, these methods are rarely available in clinical microbiology laboratories and are very expensive. And thirdly, these methods, by definition, only deliver data on blood and involve chemical determination, that is, they do not assess the antimicrobial activity, which could be different if for some reason the antibiotic was inactivated in vivo, for instance, by bacterial enzymes or by some other interaction or host factor.
- Thus, a need exists for new techniques that can quickly and inexpensively quantify a broad panel of antimicrobials that might be present in a biological sample obtained from a patient receiving antimicrobial treatment, as well as determine its effective antimicrobial activity.
- Disclosed herein are improved methods, compositions and kits for therapeutic drug monitoring (TDM) regarding the most relevant clinical antimicrobial drugs. In some embodiments, flow cytometry can be used. Antimicrobial level of the drugs can be quantified on different body fluids such as blood, urine, cerebrospinal fluid and will quickly allow, e.g., within 2 hours, the establishment of a targeted personalized treatment. This is especially important for critically ill patients with several co-morbidities such as renal and/or hepatic dysfunction.
- In one aspect, provided herein is a method for quantifying an antimicrobial in a biological sample, comprising:
- a. obtaining a biological sample from a patient receiving an antimicrobial;
- b. incubating the biological sample with a reference microbial strain and a fluorophore for detecting cell lesion;
- c. measuring a first signal of fluorescent intensity in the incubated biological sample using flow cytometry; and
- d. comparing the first signal to a calibrating curve previously generated for the antimicrobial, thereby quantifying the antimicrobial present in the biological sample.
- In some embodiments, the method can further include incubating a separate aliquot of the biological sample with a microbial strain isolated or recovered or derived from the same patient and the fluorophore, and measuring a second signal of fluorescence intensity therein using flow cytometry. In certain embodiments, the antimicrobial can be an antibiotic or an antifungal. The biological sample can be one or more of serum, plasma, urine, spinal fluid, ascitic fluid and bronchial secretion or washing. The fluorophore can be selected from DiBAC4 oxonol such as DiBAC4(3) (Bis-(1,3-Dibutylbarbituric Acid)Trimethine Oxonol), DiOC oxacarbocyanines such as DiOC18(3) (3,3′-Dioctadecyloxacarbocyanine Perchlorate), DHR (dihydrorhodamine), propidium iodide, or fluorescein diacetate (FDA) such as C-FDA (5(6)-Carboxyfluorescein diacetate). Other fluorophores known in the art can also be used. In some embodiments, the calibrating curve can be generated using different concentrations of the antimicrobial incubated with the reference microbial strain or with a microbial strain isolated from the same patient under testing.
-
FIG. 1 : Diagram showing an exemplary process of the present disclosure for determining antimicrobial concentration and efficacy in a patient receiving the treatment, so as to inform about further treatment strategy. -
FIG. 2 : Flow chart showing an exemplary process of the present disclosure for determining antimicrobial concentration and efficacy in a patient receiving the treatment, so as to inform about further treatment strategy. -
FIG. 3 : Exemplary diagram showing the protocol of Example 1. -
FIG. 4A : Graphic representation of the amount of cells at the acquisition gate of the flow cytometer after incubation with increasing concentrations of colistin; a dose-dependent effect was achieved.FIG. 4B : Flow cytometry scattergrams (SSC vs FSC) representing the morphologic changes in bacterial population with the increasing concentrations of colistin; a decrease in the population percentage is evident. -
FIG. 5A : Flow cytometry analysis of Flow cytometric TDM using the Flow-cytometry Antimicrobial Susceptibility Test (FAST) dosing kit to determine the dose-dependent effect of vancomycin upon S. aureus ATCC 29213 viability, through analysis of cell morphology visualized in scatterplots. -
FIG. 5B : Flow cytometry analysis of Flow cytometric TDM using the Flow-cytometry Antimicrobial Susceptibility Test (FAST) dosing kit to determine the dose-dependent effect of vancomycin on S. aureus ATCC 29213 viability, through analysis of the intensity of cell fluorescence. -
FIG. 6A : Control vancomycin dose curve concentration of S. aureus ATCC 29213 strain. The control dose curve effect obtained by flow cytometry showed a linear effect between 0.5 and 4 ug/ml and the coefficient of correlation was calculated. -
FIG. 6B : Representative example of a flow cytometric scattergram showing a decrease in the bacterial population (red circle) with the concomitant increase of patient vancomycin (vanco) serum concentration. - Disclosed herein is an improved therapeutic drug monitoring (TDM) assay, as well as related compositions and kits, that measures both antimicrobial levels and its efficacy in biological samples of patients using reference bacterial or fungal strains and/or, whenever available, patient-derived specific bacterial/fungal cultures. The improved TDM dosing assay and kit is based, in some embodiments, upon flow cytometry, and can provide results quickly and accurately, e.g., within 2 hours or less. This is significantly advantageous compared to conventional TDM methods.
- In some embodiments, the improved TDM disclosed herein can measure the cellular effects of a panel of antimicrobials (e.g., antibiotics in case of bacteria and/or antifungals in case of fungi), available in a biological sample such as blood or other body fluids. These phenotypical changes can be measured well before the effects on bacterial growth (which is the read-out of conventional methods) become apparent. Phenotypic changes, such as morphofuntional changes, membrane potential, specific membrane lesions or DNA quantity, can be assessed by flow cytometry, and antimicrobial drug efficacy can thus be quickly detected and quantified. These specific changes can be measured using fluorescent probes such as DiBAC4 and DIOC which are membrane-potential sensitive; propidium iodide, a probe that assesses the integrity of the cell membrane; or C-FDA, DHR or FUN-1 to evaluate the metabolic cell status. These probes have been shown to provide a convenient, fast and accurate read-out of the antibiotic effect upon bacteria and fungi.
- Following the creation of dose-effect curves (calibrating curves) for each drug, using type reference strains (from American Type Culture Collection (ATCC) for example) and serial antimicrobial concentrations, the desirable approach can be used for standardized drug concentration measurement. Essentially, the effect of the unknown concentration of specific antimicrobial in the serum sample (or other body fluid sample) obtained from the patient can be compared with the corresponding calibration curve, thus providing a fast and easy method to quantify the effective antimicrobial concentration present in the patient’s biological samples. In parallel, the same procedure can be performed with a bacterial or fungal isolate obtained from the same patient, using standard clinical microbiological procedures. Such an approach can be used to establish the effective antimicrobial concentration available in the patient’s sample against the patient-specific bacterial or fungal strain, by assessing and quantifying the cell lesion exhibited by such strain.
- In certain embodiments, various biological samples can be collected from infected patients, such as blood from blood cultures, spinal, pericardial, pleural or peritoneal fluid, urine, bronchial secretions or bronchial washing. Antimicrobial treatment can be initiated later, after Antimicrobial Susceptibility Test (AST). Based on the AST result, the antimicrobial therapy can be initiated. In cases where clinical outcome is not favorable despite the in vitro susceptibility to the drug, especially if the patient exhibits renal or hepatic dysfunction, serum or other liquid samples can be collected to quantify the amount of effective antimicrobial available at the specific site of infection to determine whether the antimicrobial is present at sufficient level at the site of infection. If not, a different (e.g., increased) amount of antimicrobial or a different antimicrobial can be administered.
- The biological sample can be incubated following different dilutions with a type or reference microbial strain and the lesion produced on the microorganism can be quantified by flow cytometry. Following comparison with standard curves the amount of active antimicrobial agent available on the biological sample can be determined.
- In case a microbial isolate has been recovered from the same patient, the TDM can be performed with this microbial isolate, instead of a reference strain. Antimicrobial effect obtained in the Antimicrobial Susceptibility Test (AST) in vitro can be compared with the effect of different concentrations of the same antimicrobial in biological samples. This can represent a significant advantage in the selection of therapeutic strategies. For example, if serum level of the antimicrobial is below the assumed therapeutic effective levels (e.g., in patients where therapeutic values are impossible to achieve) but is nevertheless higher than the to minimum inhibitory concentration (MIC) value, the antimicrobial should still be able to cause severe lesion on the microorganism infecting the patient; in that case, therapy does not need to be interrupted or substituted.
- The clinician can be informed about the concentration of the antimicrobial prescribed to a patient is above or below the therapeutic intervals, allowing the clinician to make the required adjustments.
- This improved TDM method is a microbiological functional method for antimicrobial drug quantification in patient’s biological samples. It is a functional assay, which allows the measurement of the activity of the drugs and not only their chemical presence. In addition, as the TDM disclosed herein is based upon a flow cytometric assay and not on the study of the microbe’s ability to grow, it is a very fast, reproducible and accurate method. This improved TDM method provides significant advantages over conventional methods, considering the urgent need of an inexpensive, simple and fast method to personalize dosage of antibiotics to treat severe infections. This is due to several reasons:
- (1) Blood levels of antibiotics can vary 100-1000 fold between patients when using the same dose;
- (2) Critically ill patients, especially those exhibiting altered PK/PD characteristics require fast and personalized treatment;
- (3) Dosage can only be personalized if blood levels of antibiotics and their activity are precisely known;
- (4) Conventional methods are limited to a few antimicrobials, are very cumbersome and do not measure the antimicrobial activity of the drugs since they only assess chemical presence of the drugs;
- (5) Critically ill patients have a far greater chance of being infected with drug-resistant microorganisms which reduces the therapeutic choices and possibilities of a favorable outcome; and
- (6) Infection by drug-resistant microorganisms, in particular bacteria and fungi represents a growing threat in Europe and USA, making the need for personalized dosing especially urgent and mandatory.
- In addition, the methods and compositions disclosed herein can also be used in other applications such as:
- (1) Antimicrobial dosing in water for environmental monitoring/bioremediation purposes;
- (2) Quality control of antimicrobial drugs, such us variation between different providers and/or different lots;
- (3) Antimicrobial monitoring of banned drugs, in order to ensure food safety; application in raw food (meat, plant) extracts or animal body fluids;
- (4) In veterinary medicine, with the same purposes as above described in clinical medicine for humans.
- Additional features of the present disclosure are described in the following non-limiting Examples. It is to be understood, however, that these examples are included solely for the purpose of exemplifying aspects of the present disclosure. They should not be understood in any way as a restriction of the broad description of the disclosure as set out above.
- Colistin is increasingly being prescribed as a rescue treatment for infections with multidrug-resistant bacilli. Colistin is an old antimicrobial but, is at present, the only alternative against superbug strains like those producing carbapenemases, and multi-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Since its pharmacokinetics is not yet well known, it would be very useful to have the possibility to measure its antibacterial activity in each individual patient receiving it. Often, nephrotoxicity and, to a lesser degree, neurotoxicity can occur during systemic colistin therapy; such adverse side effects have severely limited colistin use in the past. However, these effects are largely reversible and can be managed through close drug monitoring. We have developed a microbiological assay in order to quantify the antimicrobial effect produced by different antimicrobial drugs using flow cytometry, including colistin.
- The objective of this example was to optimize the measurement of the antimicrobial activity of colistin in the patient blood using flow cytometry.
- Serial dilutions of colistin (Sigma), ranging between 0.008 and 2 µg/ml, were inoculated in human plasma (free of colistin) and incubated with
E . coli ATCC 25922 during 60 minutes and afterwards stained with a fluorescent dye and analyzed in a flow cytometer (Accuri, BD) using a protocol previously optimized (FIG. 3 ): a flow cytometric template of cell analysis was defined in order to include the majority of the bacterial population and at least 20,000 cells are analyzed according size, complexity and intensity of fluorescence on the different fluorescent channels. - Morphological changes were evident on the bacterial cell population following exposure to serial increasing concentrations of colistin (
FIG. 4A ). Regarding the intensity of fluorescence, a linear effect occurred at concentrations between 0.06 and 1 µg/mL of colistin (FIG. 4B ). The effect of higher colistin concentrations could be confirmed after diluting the serum. - Thus, a sensitive and accurate method was developed allowing, in a short time(60 minutes) to quantify the number of colistin impaired cells and conclude about the serum concentration of the active drug. This protocol will be very relevant for critical care patients receiving colistin with low or no clinical improvement. For this assay, a quality control strain or, whenever possible, the own patient isolate could be used for the design of a standard dose-effect curve.
- Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as an alternative to penicillin to inhibit penicillinase-producing strains of Staphylococcus aureus. Despite limitations such as poor tissue penetration, relatively slow antibacterial effect, and the potential for toxicity, vancomycin is regarded as the gold standard for antibiotic treatment of MRSA infections because of its low cost and established clinical response. Due to the complexity of vancomycin pharmacokinetics and its high toxicity, the monitoring of blood level is recommended in order to obtain therapeutic success. Our research group has been using flow cytometry to evaluate the in vitro susceptibility profile of bacteria with great success, including to vancomycin.
- The objective of this work was to optimize the microbiology measurement of the activity of vancomycin in the patient’s blood using flow cytometry.
- Material and Methods. S. aureus ATCC 29213 was incubated for 1 hour with serial concentrations of vancomycin (4 µg/ml to 0.03 µg/ml) in donor drug free human serum and stained with adequate fluorochrome. The intensity of fluorescence and the changes in the scattergram of the bacterial population were recorded after flow cytometry analysis. Twenty samples of serum collected from patients receiving vancomycin were obtained from the biochemistry lab. The vancomycin drug concentrations were analyzed by Architect iVancomycin (Abbott) using the Architect i1000 SR analyzer (Abbott). Architect iVancomycin is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative measurement of vancomycin in human serum or plasma. In parallel, serum samples were incubated with the S. aureus control strain, after 10 serial dilutions (1:2) and analyzed by flow cytometry (Accury, BD) according the protocol described in Example 1. A flow cytometric template of cell analysis was defined in order to include the majority of the bacterial population. A comparison of the concentrations obtained with the Architect iVancomycin method and with the new flow cytometric method was performed using Student’s T test.
- As shown in
FIGS. 5A and 5B , following incubation of S. aureus (susceptible to low concentrations) with increasing concentration of vancomycin, a dose effect cellular lesion is evident by: the reduction on the cell density plot (percentage of cells on P1,FIG. 5A ) and an increase of the intensity of fluorescence (FIG. 5B ), both facts indicating cell damage. - The control dose curve effect obtained by flow cytometry showed a linear effect between 1 and 0.03 µg/ml and the coefficient of correlation was calculated (
FIG. 6A ). Patient’s serum sample concentration was calculated using linear regression equation obtained from the control curve. Specifically, the concentration of vancomycin in the serum patient sample was determined by using the % of viable cells obtained inFIG. 6B (red square) that was within the linearity range, and taking into consideration the serum dilution factor. An excellent correlation between both methods was obtained, with a variation of vancomycin concentration in serum patients of ±5 µg/ml. - Conclusions. A new, simple, convenient and fast method for quantification of vancomycin activity in biological samples was obtained with the advantage of being a fast and functional method reflecting drug antimicrobial activity.
- Modifications and variations of the described methods and compositions of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the disclosure. Although the disclosure has been described in connection with specific embodiments, it should be understood that the disclosure as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the disclosure are intended and understood by those skilled in the relevant field in which this disclosure resides to be within the scope of the disclosure as represented by the following claims.
- All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
Claims (22)
1. A method for quantifying an antimicrobial in a biological sample, comprising:
incubating a biological sample with a reference microbial strain and a fluorophore for detecting cell lesion, wherein the biological sample is obtained from a patient receiving an antimicrobial;
measuring, using flow cytometry, a first signal of fluorescent intensity of the fluorophore in the biological sample incubated with the reference microbial strain; and
comparing the first signal to a calibrating curve previously generated for the antimicrobial against the reference microbial strain, thereby quantifying the antimicrobial present in the biological sample.
2. The method of claim 1 , wherein the biological sample is one or more of serum, plasma, urine, spinal fluid, bronchial secretions or washing or any other body fluid.
3. The method of claim 1 , wherein the patient has an infection.
4. The method of claim 1 , wherein the antimicrobial is an antibiotic or antifungal.
5. The method of claim 1 , wherein the reference microbial strain is E. coli or S. aureus.
6. The method of claim 1 , wherein the fluorophore is selected from DiBAC4, DIOC, propidium iodide, DHR, C-FDA or FUN-1.
7. The method of claim 1 , wherein the incubating step comprises incubating for about 60 minutes.
8. The method of claim 1 , wherein the calibrating curve is generated using different concentrations of the antimicrobial incubated with the reference microbial strain.
9. The method of claim 1 , further comprising incubating a separate aliquot of the biological sample with a microbial strain isolated from the patient and the fluorophore, and measuring a second signal of fluorescent intensity in the separate aliquot using flow cytometry.
10. The method of claim 9 , wherein the calibrating curve is generated using different concentrations of the antimicrobial incubated with the microbial strain isolated from the patient.
11. The method of claim 9 , wherein the microbial strain isolated from the patient is E. coli or S. aureus.
12. A method for quantifying an antimicrobial in a biological sample, comprising:
incubating a biological sample obtained from a patient receiving an antimicrobial with a reference microbial strain and a fluorophore for detecting a cell lesion;
before an effect on microbial growth becomes apparent, measuring a first signal of fluorescent intensity of the fluorophore in the biological sample incubated with the reference microbial strain using flow cytometry; and
comparing the first signal to a calibrating curve previously generated for the antimicrobial against the reference microbial strain, thereby quantifying the antimicrobial present in the biological sample.
13. The method of claim 12 , wherein the biological sample is one or more of serum, plasma, urine, spinal fluid, bronchial secretions or washing or any other body fluid.
14. The method of claim 12 , wherein the patient has an infection.
15. The method of claim 12 , wherein the antimicrobial is an antibiotic or antifungal.
16. The method of claim 12 , wherein the reference microbial strain is E. coli or S. aureus.
17. The method of claim 12 , wherein the fluorophore is selected from DiBAC4, DIOC, propidium iodide, DHR, C-FDA or FUN-1.
18. The method of claim 12 , wherein the incubating step comprises incubating for about 60 minutes.
19. The method of claim 12 , wherein the calibrating curve is generated using different concentrations of the antimicrobial incubated with the reference microbial strain.
20. The method of claim 12 , further comprising incubating a separate aliquot of the biological sample with a microbial strain isolated from the patient and the fluorophore, and measuring a second signal of fluorescent intensity in the separate aliquot using flow cytometry.
21. The method of claim 20 , wherein the calibrating curve is generated using different concentrations of the antimicrobial incubated with the microbial strain isolated from the patient.
22. The method of claim 20 , wherein the microbial strain isolated from the patient is E. coli or S. aureus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/051,360 US20230227887A1 (en) | 2017-06-02 | 2022-10-31 | Therapeutic Drug Monitoring |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762514323P | 2017-06-02 | 2017-06-02 | |
PCT/PT2018/050021 WO2018222061A1 (en) | 2017-06-02 | 2018-06-01 | Improved therapeutic drug monitoring |
US201916617817A | 2019-11-27 | 2019-11-27 | |
US18/051,360 US20230227887A1 (en) | 2017-06-02 | 2022-10-31 | Therapeutic Drug Monitoring |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2018/050021 Continuation WO2018222061A1 (en) | 2017-06-02 | 2018-06-01 | Improved therapeutic drug monitoring |
US16/617,817 Continuation US11485993B2 (en) | 2017-06-02 | 2018-06-01 | Therapeutic drug monitoring |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230227887A1 true US20230227887A1 (en) | 2023-07-20 |
Family
ID=62837968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/617,817 Active 2039-07-06 US11485993B2 (en) | 2017-06-02 | 2018-06-01 | Therapeutic drug monitoring |
US18/051,360 Pending US20230227887A1 (en) | 2017-06-02 | 2022-10-31 | Therapeutic Drug Monitoring |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/617,817 Active 2039-07-06 US11485993B2 (en) | 2017-06-02 | 2018-06-01 | Therapeutic drug monitoring |
Country Status (7)
Country | Link |
---|---|
US (2) | US11485993B2 (en) |
EP (1) | EP3630997B1 (en) |
JP (1) | JP7209644B2 (en) |
BR (1) | BR112019025501A2 (en) |
ES (1) | ES2910202T3 (en) |
PT (1) | PT3630997T (en) |
WO (1) | WO2018222061A1 (en) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8305324D0 (en) * | 1983-02-25 | 1983-03-30 | Unilever Plc | Microbiological test processes |
JPH0538298A (en) | 1991-08-07 | 1993-02-19 | Mercian Corp | Detection of aminoglycoside antibiotic |
PL184460B1 (en) | 1995-02-01 | 2002-10-31 | Gist Brocades Bv | Quick microbiological test for detecting antibacterial compounds |
CN101790683B (en) | 2007-08-31 | 2015-02-11 | 国立血清研究所 | Compositions and means for diagnosing microbial infections |
EP2245178B1 (en) | 2008-02-01 | 2014-12-24 | miacom Diagnostics GmbH | Identification of antibiotic resistance using labelled antibiotics |
CA2760203C (en) | 2009-05-07 | 2018-10-23 | Biomerieux, Inc. | Methods for antimicrobial resistance determination |
PL2714922T3 (en) | 2011-06-03 | 2018-02-28 | Universidade Do Porto | Method of detecting the resistant microorganisms to a therapeutic agent |
US9382572B2 (en) * | 2013-08-23 | 2016-07-05 | Ecolab Usa Inc. | Methods of determining biocide efficacy or mechanism of action using flow cytometry |
EP3069139A4 (en) | 2013-11-12 | 2016-12-07 | Stanford Res Inst Int | Bacterial diagnosis |
CL2013003628A1 (en) * | 2013-12-18 | 2015-02-13 | Univ Santiago Chile | Method for the microbiological determination of traces of antibiotics in biological samples of low volume |
MX2019000459A (en) | 2016-07-28 | 2019-04-22 | Victor Equipment Co | Fuel tip with integrated flashback arrestor. |
WO2018203315A1 (en) | 2017-05-05 | 2018-11-08 | Universidade Do Porto | Method for microorganism extraction and/or for determination of a microorganism main resistance mechanism and/or the minimum inhibitory concentration of a therapeutical agent, kits and uses thereof |
-
2018
- 2018-06-01 BR BR112019025501-0A patent/BR112019025501A2/en unknown
- 2018-06-01 PT PT187377353T patent/PT3630997T/en unknown
- 2018-06-01 ES ES18737735T patent/ES2910202T3/en active Active
- 2018-06-01 JP JP2019566649A patent/JP7209644B2/en active Active
- 2018-06-01 US US16/617,817 patent/US11485993B2/en active Active
- 2018-06-01 WO PCT/PT2018/050021 patent/WO2018222061A1/en unknown
- 2018-06-01 EP EP18737735.3A patent/EP3630997B1/en active Active
-
2022
- 2022-10-31 US US18/051,360 patent/US20230227887A1/en active Pending
Non-Patent Citations (2)
Title |
---|
Gauthier, Christian, Yves St-Pierre, and Richard Villemur. "Rapid antimicrobial susceptibility testing of urinary tract isolates and samples by flow cytometry." Journal of medical microbiology 51.3 (2002): 192-200. (Year: 2002) * |
Martin, Edith, Ute Schlasius, and Sucharit Bhakdi. "Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum." Medical microbiology and immunology 181 (1992): 117-126. (Year: 1992) * |
Also Published As
Publication number | Publication date |
---|---|
EP3630997B1 (en) | 2021-12-29 |
US20200190554A1 (en) | 2020-06-18 |
JP2020521501A (en) | 2020-07-27 |
EP3630997A1 (en) | 2020-04-08 |
WO2018222061A1 (en) | 2018-12-06 |
JP7209644B2 (en) | 2023-01-20 |
PT3630997T (en) | 2022-04-05 |
BR112019025501A2 (en) | 2020-06-23 |
US11485993B2 (en) | 2022-11-01 |
ES2910202T3 (en) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Puttaswamy et al. | A comprehensive review of the present and future antibiotic susceptibility testing (AST) systems | |
US20220243248A1 (en) | Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics | |
Phadwal et al. | A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells | |
ES2652367T3 (en) | Method of detection of microorganisms resistant to a therapeutic agent | |
Hu et al. | Serum D-dimer as a diagnostic index of PJI and retrospective analysis of etiology in patients with PJI | |
US10668115B2 (en) | Stable probiotic composition containing Bacillus coagulans MTCC 5856 and method of detection thereof | |
Gauthier et al. | Rapid antimicrobial susceptibility testing of urinary tract isolates and samples by flow cytometry | |
Walberg et al. | Rapid flow cytometric assessment of mecillinam and ampicillin bacterial susceptibility | |
Suller et al. | A flow cytometric study of antibiotic-induced damage and evaluation as a rapid antibiotic susceptibility test for methicillin-resistant Staphylococcus aureus. | |
Díez-Aguilar et al. | Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates | |
Jacobson et al. | Comparison of Neisseria gonorrhoeae minimum inhibitory concentrations obtained using agar dilution versus microbroth dilution methods | |
Zhang et al. | Rapid antimicrobial susceptibility testing by stimulated Raman scattering metabolic imaging and morphological deformation of bacteria | |
US20230227887A1 (en) | Therapeutic Drug Monitoring | |
Di Domenico et al. | The clinical Biofilm Ring Test: a promising tool for the clinical assessment of biofilm-producing Candida species | |
Williams | Prospects for standardisation of methods and guidelines for disc susceptibility testing | |
Kansak et al. | Rapid detection of fosfomycin resistance in Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections | |
Fang et al. | A fluorometric β-glucuronidase assay for analysis of bacterial growth in milk | |
Stratton | Advanced phenotypic antimicrobial susceptibility testing methods | |
Sugandhi et al. | Prevalence of yeast in diabetic foot infections | |
Puşcaş et al. | Micro-test system for rapid isolation and identification of Candida species in urinary tract infections | |
EP3740585B1 (en) | Improving detection of microorganisms | |
JP2000316597A (en) | Method for discriminating bacterium for producing expanded substrate type beta-lactamase(esbl) | |
Manoni et al. | Measurement of urine leukocytes by a second generation flow cytometer: application in the diagnosis of acute urinary tract infections in adult patients | |
KR20220066727A (en) | Method for evaluating antibiotic susceptibility of microorganisms by image analysis | |
Thusoo | Antimicrobial Resistance:-Introduction and Methods for Detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FASTINOV S.A., PORTUGAL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AZEVEDO PINA VAZ, CIDALIA IRENE;AGOSTINHO GONCALVES RODRIGUES, ACACIO;REEL/FRAME:063575/0877 Effective date: 20200313 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |